Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239083 | 0.95 | PRCP (0.45) | PRCPKCNH2HRH3SLC18A3DRD2 | |
| SCHEMBL26238974 | 0.88 | CCR1 (0.44) | KCNH2CCR1 | |
| SCHEMBL26238973 | 0.86 | KCNQ2 (0.48) | PRCPKCNH2LIPE | |
| SCHEMBL26238904 | 0.84 | SLC18A3 (0.44) | PRCPKCNH2HRH3SLC18A3DRD2 | |
| SCHEMBL26238970 | 0.84 | TRPV1 (0.44) | KCNH2OPRM1 | |
| SCHEMBL26238901 | 0.83 | DRD2 (0.48) | SLC18A3DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL26238969 | 0.83 | CHRM4 (0.44) | DRD2 | |
| SCHEMBL26238971 | 0.81 | MEN1 (0.50) | KCNH2DRD2 | |
| SCHEMBL26238902 | 0.81 | KCNH2 (0.47) | PRCPKCNH2HRH3OPRM1CCR1 | |
| SCHEMBL26238903 | 0.81 | KCNH2 (0.47) | PRCPKCNH2HRH3OPRM1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4472947-A1 | SWEETENER COMPOSITIONS | Firmenich Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | GPR119, TAS2R50, TAS2R30 | PRCP 1490/4885KCNH2 3794/4885HRH3 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.